Home/Pipeline/HS-10374

HS-10374

Depression

Phase IIIActiveNCT05808369

Key Facts

Indication

Depression

Phase

Phase III

Status

Active

Company

Hansoh Pharma

About Hansoh Pharma

Hansoh Pharma's mission is to develop and deliver innovative, high-quality medicines that address significant unmet medical needs in China and worldwide. The company has achieved a dominant position as one of China's most valuable pharmaceutical entities, built upon the commercial success of flagship products and a rich pipeline of novel candidates. Its strategy leverages a fully integrated platform from discovery to commercialization, with a sharp focus on oncology and CNS disorders, while actively pursuing strategic global partnerships to expand its international footprint. Hansoh's substantial R&D investment and manufacturing scale underpin its ambition to become a global biopharmaceutical leader.

View full company profile

Therapeutic Areas

Oncology Central Nervous System Disorders Anti-infectives Diabetes/Metabolic Diseases

Other Depression Drugs

Drug	Company	Phase	Status
Depression Clinical Trials	IMA Clinical Research	Not Applicable (Service)	Active
Depression Study	Sun Valley Research Center	Not Disclosed	Active
eTNS Platform	NeuroSigma	Unknown	Active
ALM003	Almatica Pharma	Phase 3	Active
ALM014	Almatica Pharma	Pivotal BA/BE	Active
NRCT-101SR	Neurocentria	Phase 2b/3	Active
Starstim for Depression	Neuroelectrics	Phase 1/2	Active
Depression Biomarkers	Paradise Genomics	Discovery	Active
Home-tDCS Depression Trial	Soterix Medical	N/A (Device-enabled trial)	Active
BPL-003	AtaiBeckley	Phase 2	Active
VLS-01	AtaiBeckley	Phase 2	Active
SVN-015	Solvonis Therapeutics	Pre-clinical	Active (Expansion)